CNL
MCID: CHR286
MIFTS: 38

Chronic Neutrophilic Leukemia (CNL)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Chronic Neutrophilic Leukemia

MalaCards integrated aliases for Chronic Neutrophilic Leukemia:

Name: Chronic Neutrophilic Leukemia 12 53 59 15 73
Leukemia Neutrophilic Chronic 55
Cnl 53

Characteristics:

Orphanet epidemiological data:

59
chronic neutrophilic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0080187
NCIt 50 C3179
Orphanet 59 ORPHA86829
ICD10 via Orphanet 34 D47.1
MESH via Orphanet 45 D015467
UMLS via Orphanet 74 C0023481
UMLS 73 C0023481

Summaries for Chronic Neutrophilic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene.

MalaCards based summary : Chronic Neutrophilic Leukemia, also known as leukemia neutrophilic chronic, is related to chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. An important gene associated with Chronic Neutrophilic Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways is Hematopoietic cell lineage. The drugs Ketamine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, bone and bone marrow, and related phenotype is Reduced mammosphere formation.

Wikipedia : 76 Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent... more...

Related Diseases for Chronic Neutrophilic Leukemia

Diseases related to Chronic Neutrophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 chronic myelomonocytic leukemia 30.0 ASXL1 CSF3R SETBP1
2 atypical chronic myeloid leukemia 29.9 ASXL1 CSF3R SETBP1
3 severe congenital neutropenia 29.6 CSF3 CSF3R
4 myelofibrosis 28.8 ASXL1 CALR CSF3 SRSF2
5 myelodysplastic syndrome 28.5 ASXL1 CSF3 CSF3R KMT2A SETBP1 SRSF2
6 myeloproliferative neoplasm 11.2
7 leukemia 10.8
8 pdgfrb-associated chronic eosinophilic leukemia 10.2
9 polycythemia vera 10.1
10 polycythemia 10.1
11 myeloma, multiple 10.1
12 myeloid leukemia 10.1
13 pulmonary alveolar microlithiasis 10.0
14 blood group--swann system 10.0
15 monoclonal gammopathy of uncertain significance 10.0
16 hypertrichosis 9.9 ASXL1 KMT2A
17 hematopoietic stem cell transplantation 9.9
18 neutropenia 9.9
19 primary polycythemia 9.9 ASXL1 CALR
20 myelodysplastic myeloproliferative cancer 9.9 ASXL1 CSF3R SETBP1
21 hematologic cancer 9.9 CSF3 CSF3R KMT2A
22 aplastic anemia 9.8 ASXL1 CSF3 CSF3R
23 leukemia, chronic lymphocytic 2 9.8
24 leukemia, chronic lymphocytic 9.8
25 hemophilia a 9.8
26 cerebral hemorrhage 9.8
27 lymphocytic leukemia 9.8
28 nephrotic syndrome 9.8
29 plasma cell neoplasm 9.8
30 mucormycosis 9.8
31 amyloidosis 9.8
32 miliary tuberculosis 9.8
33 hemophilia 9.8
34 acquired hemophilia 9.8
35 acquired hemophilia a 9.8
36 leukemia, b-cell, chronic 9.8
37 leukemia, chronic myeloid 9.7 CSF3 CSF3R KMT2A SETBP1
38 bone marrow cancer 9.7 CALR CSF3 CSF3R KMT2A
39 chronic leukemia 9.6 ASXL1 CSF3R SETBP1 SRSF2
40 leukemia, acute myeloid 9.3 ASXL1 CSF3 CSF3R KMT2A SETBP1 SRSF2

Graphical network of the top 20 diseases related to Chronic Neutrophilic Leukemia:



Diseases related to Chronic Neutrophilic Leukemia

Symptoms & Phenotypes for Chronic Neutrophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 CALR CSF3 CSF3R KMT2A

Drugs & Therapeutics for Chronic Neutrophilic Leukemia

Drugs for Chronic Neutrophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Mycophenolic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
3
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Acyclovir Approved Phase 3 59277-89-3 2022
6
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
7
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
8
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
9
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
10
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
11
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
12 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
13
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
14
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
15
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
16
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
17 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
18 Anesthetics, Dissociative Phase 3
19 Anesthetics, General Phase 3
20 Excitatory Amino Acid Antagonists Phase 3
21 Excitatory Amino Acids Phase 3
22 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
23 Analgesics Phase 3,Not Applicable
24 Anesthetics, Intravenous Phase 3
25 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
26 Anesthetics Phase 3
27 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
32 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antitubercular Agents Phase 3,Phase 1,Phase 2,Not Applicable
37 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
38 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2
39 Calcium, Dietary Phase 3,Phase 1,Phase 2,Not Applicable
40 Ophthalmic Solutions Phase 3,Phase 1,Phase 2
41 Cyclosporins Phase 3,Phase 1,Phase 2,Not Applicable
42 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1,Not Applicable
43 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Narcotics Phase 3,Not Applicable
45 Analgesics, Opioid Phase 3,Not Applicable
46 Cola Phase 3,Phase 1
47 Adjuvants, Anesthesia Phase 3
48 Liver Extracts Phase 3,Phase 1
49 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 valacyclovir Phase 3

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
3 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
4 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
10 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
11 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
12 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
14 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
15 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
16 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
17 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
18 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
19 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
20 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
21 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
22 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
23 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
24 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
25 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
26 Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer Completed NCT00134017 Phase 2 Busulfan;Cyclophosphamide
27 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
28 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
29 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
30 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
31 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
32 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
33 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
34 Bone Marrow Transplant in Treating Patients With Hematologic Cancers Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
35 Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00005622 Phase 2 cyclophosphamide
36 Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Recruiting NCT02092324 Phase 2 Ruxolitinib Phosphate
37 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
38 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
39 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox
40 Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
41 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
42 Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Terminated NCT00617929 Phase 2 clofarabine
43 Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer Terminated NCT00295880 Phase 1, Phase 2
44 Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
45 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
46 Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
47 Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
48 Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections Unknown status NCT00769613 Phase 1
49 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Completed NCT01484015 Phase 1 cefepime hydrochloride
50 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206

Search NIH Clinical Center for Chronic Neutrophilic Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Chronic Neutrophilic Leukemia

Anatomical Context for Chronic Neutrophilic Leukemia

MalaCards organs/tissues related to Chronic Neutrophilic Leukemia:

41
Neutrophil, Bone, Bone Marrow, Myeloid, T Cells, Liver, Nk Cells

Publications for Chronic Neutrophilic Leukemia

Articles related to Chronic Neutrophilic Leukemia:

(show top 50) (show all 136)
# Title Authors Year
1
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. ( 29449543 )
2018
2
Chronic neutrophilic leukemia. ( 29686565 )
2018
3
Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. ( 29512199 )
2018
4
Chronic neutrophilic leukemia. ( 29473201 )
2018
5
Chronic neutrophilic leukemia: new science and new diagnostic criteria. ( 29440636 )
2018
6
Chronic neutrophilic leukemia, an extremely rare cause of neutrophilia in childhood: Cure with hematopoietic stem cell transplantation. ( 29676020 )
2018
7
Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. ( 29587671 )
2018
8
Colony-stimulating Factor 3 Receptor Mutated Chronic Neutrophilic Leukemia: A Rare Case Report. ( 30473959 )
2018
9
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. ( 28158286 )
2017
10
Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. ( 28302714 )
2017
11
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. ( 28983816 )
2017
12
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. ( 27789332 )
2017
13
Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. ( 28209656 )
2017
14
Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. ( 28762112 )
2017
15
Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. ( 28209919 )
2017
16
Chronic neutrophilic leukemia in a child with a CSF3R T618I germline mutation. ( 27581359 )
2016
17
Genomics of chronic neutrophilic leukemia. ( 28028025 )
2016
18
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. ( 27068405 )
2016
19
A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications. ( 26875968 )
2016
20
Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. ( 26700908 )
2016
21
Dao K-HT, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia? Hematology Am Soc Hematol Educ Program. 2015;2015:264-271. ( 27913552 )
2016
22
Sweet's syndrome associated with chronic neutrophilic leukemia. ( 25751350 )
2015
23
What's different about atypical CML and chronic neutrophilic leukemia? ( 26637732 )
2015
24
Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report. ( 26622734 )
2015
25
Chronic neutrophilic leukemia: a clinical perspective. ( 26366092 )
2015
26
T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation. ( 25932451 )
2015
27
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. ( 25480691 )
2015
28
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. ( 25850813 )
2015
29
A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. ( 25983565 )
2015
30
Splenic rupture in primary amyloidosis with chronic neutrophilic leukemia. ( 25830123 )
2015
31
Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. ( 25575036 )
2015
32
Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. ( 26137042 )
2015
33
Chronic neutrophilic leukemia with plasma cell dyscrasia: friends or relatives? ( 23656197 )
2014
34
Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. ( 24445868 )
2014
35
CALR mutation studies in chronic neutrophilic leukemia. ( 24421250 )
2014
36
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
37
Nephrotic syndrome related to chronic neutrophilic leukemia. ( 25366011 )
2014
38
CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. ( 25316523 )
2014
39
Treatment of coexisting chronic neutrophilic leukemia and light chain multiple myeloma with hydroxyurea, bortezomib, and dexamethasone. ( 25143840 )
2014
40
Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management. ( 24845374 )
2014
41
Chronic Neutrophilic Leukemia with V617F JAK2 Mutation. ( 24839370 )
2014
42
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
43
Chronic neutrophilic leukemia: a rare case report. ( 25332542 )
2014
44
Current strategies in the diagnosis and management of chronic neutrophilic leukemia. ( 25533830 )
2014
45
CSF3R is mutated in chronic neutrophilic leukemia and atypical CML. ( 23847367 )
2013
46
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. ( 23604229 )
2013
47
Pregnancy in a woman with chronic neutrophilic leukemia. ( 23344408 )
2013
48
The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. ( 23896413 )
2013
49
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. ( 23656643 )
2013
50
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. ( 24203930 )
2013

Variations for Chronic Neutrophilic Leukemia

Expression for Chronic Neutrophilic Leukemia

Search GEO for disease gene expression data for Chronic Neutrophilic Leukemia.

Pathways for Chronic Neutrophilic Leukemia

Pathways related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.61 CSF3 CSF3R

GO Terms for Chronic Neutrophilic Leukemia

Sources for Chronic Neutrophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....